Study of Lanadelumab Takhzyro in Teens and Adults with Hereditary Angioedema Type 1 or 2 Assessing Treatment Effectiveness and Quality of Life in Saudi Arabia

What this Trial Is About

Hereditary angioedema HAE is a rare condition causing sudden swelling under the skin and inside the body, such as in the belly, throat, or genitals. This swelling is due to temporary blood vessel leaks and does not cause itching or hives. The study focuses on people with HAE-C1INH Type 1 or 2 who have been using Takhzyro4 lanadelumab to prevent HAE attacks, aiming to evaluate how well this treatment reduces disease activity in everyday life after 6 to 12 months of use. This observational study will collect retrospective clinical data from medical records for participants diagnosed with HAE-C1INH Type 1 or 2 who started long-term prophylaxis with Takhzyro4. Data from before the first Takhzyro4 dose pre-index and at least 6 months after the first dose post-index will be examined to assess treatment outcomes. No new treatment will be given as part of the study. Participants medical records will be reviewed to track changes in HAE activity scores, quality of life, and attack frequency before and after treatment, with data collected between September 2025 and February 2026. The study will also explore factors affecting treatment response. Follow-up can last up to 12 months after the first Takhzyro4 dose unless treatment stops, the patient dies, or is lost to follow-up.

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia